Estriol for Multiple Sclerosis

[Joann]

Synthetic Biologics, Inc. announced today that patient enrollment has been completed in a Phase II clinical trial evaluating the efficacy and safety of Synthetic Biologics' proprietary oral formulation of estriol (Trimesta(TM)) for the treatment of relapsing-remitting multiple sclerosis (MS). With over $8 million in external grant funding awarded to date, this Trimesta clinical trial should be fully funded to its completion.

http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/1878